venBio Partners LLC
Long book
$280.6M
Q1 2026
Positions
6
Top-10 weight
100%
concentration
Last quarter
+18.3%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsvenBio Partners LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $280.6M US long book across 6 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: PHARVARIS NV, ALUMIS INC, ALX ONCOLOGY HOLDINGS INC, HARMONY BIOSCIENCES HOLDINGS, LYELL IMMUNOPHARMA INC.
Over the last 9 quarters its long book ran on average 1.4pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-29.6%
Q2 2024
-18.9%
Q3 2024
-10.4%
Q4 2024
-26.4%
Q1 2025
-5.1%
Q2 2025
+46.1%
Q3 2025
+26.2%
Q4 2025
+28.0%
Q1 2026
+18.3%
Sector allocation
Healthcare 100%
Long book by quarter
What does venBio Partners own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PHVS PHARVARIS NV | Healthcare | 4.6M | $131.1M | 46.7% | Held |
| ALMS ALUMIS INC | Healthcare | 4.5M | $99.8M | 35.6% | -2.0% |
| ALXO ALX ONCOLOGY HOLDINGS INC | Healthcare | 12.9M | $25.8M | 9.2% | +32.8% |
| HRMY HARMONY BIOSCIENCES HOLDINGS | Healthcare | 489.2K | $13.7M | 4.9% | Held |
| LYEL LYELL IMMUNOPHARMA INC | Healthcare | 337.7K | $6.8M | 2.4% | Held |
| ARTV ARTIVA BIOTHERAPEUTICS INC | Healthcare | 531.3K | $3.4M | 1.2% | -18.1% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 6 | $280.6M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 6 | $216.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 6 | $176.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 6 | $114.8M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 7 | $123.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 7 | $170.7M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 6 | $194.3M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 6 | $231.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 5 | $281.9M | canonical | SEC ↗ |